PXMTF (PHAXIAM Therapeutics) Other Stockholders Equity: $0.00 Mil (As of Sep. 2023)


PXMTF PHAXIAM Therapeutics SA PXMTF
38 GF Score
Price $0.00
View Full Analysis

What is PHAXIAM Therapeutics Other Stockholders Equity?

PHAXIAM Therapeutics PXMTF 38 Other Stockholders Equity is $0.00 Mil as of Sep. 2023. GuruFocus rates PXMTF with a GF Score™ of 38/100.

PHAXIAM Therapeutics's Other Stockholders Equity for the quarter that ended in Sep. 2023 was $0.00 Mil.

PHAXIAM Therapeutics's quarterly Other Stockholders Equity declined from Dec. 2022 ($0.00 Mil) to Jun. 2023 ($0.00 Mil) and declined from Jun. 2023 ($0.00 Mil) to Sep. 2023 ($0.00 Mil).

PHAXIAM Therapeutics's annual Other Stockholders Equity declined from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($0.00 Mil) and declined from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil).

PHAXIAM Therapeutics Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for PHAXIAM Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PHAXIAM Therapeutics Other Stockholders Equity Chart

PHAXIAM Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 -0.00 0.00 0.00 0.00

PHAXIAM Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 0.00 0.00 0.00
PXMTF
38GF Score
PHAXIAM Therapeutics SA PXMTF
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PHAXIAM Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $0.00 Mil mean?
PHAXIAM Therapeutics (PXMTF) has a Other Stockholders Equity of $0.00 Mil as of Sep. 2023. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on PHAXIAM Therapeutics and its competitors.
Is PHAXIAM Therapeutics' Other Stockholders Equity too high?
PHAXIAM Therapeutics' current Other Stockholders Equity is $0.00 Mil. Overall, PHAXIAM Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does PHAXIAM Therapeutics' Other Stockholders Equity compare to VRTX and REGN?
PHAXIAM Therapeutics' Other Stockholders Equity of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on PHAXIAM Therapeutics and its competitors. PHAXIAM Therapeutics's current Other Stockholders Equity is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PHAXIAM Therapeutics stock overvalued right now?
PHAXIAM Therapeutics (PXMTF) has a current Other Stockholders Equity of $0.00 Mil. The current Other Stockholders Equity is $0.00 Mil. PHAXIAM Therapeutics' overall GF Score™ is 38/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For PHAXIAM Therapeutics (PXMTF), the current Other Stockholders Equity is $0.00 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PHAXIAM Therapeutics Business Description

Address 60 Avenue Rockefeller, Lyon, FRA, 69008
PHAXIAM Therapeutics SA is a clinical-stage biopharmaceutical company developing therapies for severe forms of cancer and orphan diseases. Its platform uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its product candidate eryaspase, also referred to as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple-negative breast cancer, or TNBC.
38GF Score

Get the complete analysis for PXMTF

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price